Pfizer shares fall after a muted 2026 outlook, with projected modest revenue growth, lower COVID sales and deal dilution weighing on investor sentiment.

Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer medicines as well as a robust pipeline of cancer candidates with a focus on ...

NEW YORK – Pfizer on Tuesday updated investors on efforts to move its precision oncology products into earlier lines of treatment and highlighted recent results from studies of its BRAF and MEK ...

Pfizer Inc. announced updated follow-up results from the single-arm phase 2 PHAROS trial evaluating Braftovi (encorafenib) + Mektovi binimetinib) for the treatment of adults with metastatic non-small ...

Pfizer Inc. - Business Wire - Sun Oct 19, 1:30AM CDT At the time of this analysis, the safety profile of BRAFTOVI + MEKTOVI was consistent with previous findings. The most common (≥30%) ...

Pfizer Inc. (NYSE: PFE) today announced updated follow-up results from the single-arm Phase 2 PHAROS trial evaluating BRAFTOVI ® (encorafenib) + MEKTOVI ® (binimetinib) for the treatment of adults ...

At the time of this analysis, the safety profile of BRAFTOVI + MEKTOVI was consistent with previous findings. The most common (?30%) treatment-related adverse events were nausea (52%), diarrhea (44%), ...

BRAFTOVI + MEKTOVI continued to show a substantial median overall survival benefit of 47.6 months in treatment-naïve patients with BRAF V600E-mutant metastatic non-small cell lung cancer after ...